The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs, Chapter 5 S. Gaetani, P. Dipasquale, A. Romano, L. Righetti, T. Cassano, D. Piomelli, V. Cuomo, International Review of Neurobiology, 2009, 85, 57-72 DOI: 10.1016/S0074-7742(09)85005-8 https://www.researchgate.net/publication/26675793_Chapter_5_The_Endocannabinoid_System_as_A_Target_for_Novel_Anxiolytic_and_Antidepressant_Drugs I. The Endogenous Cannabinoid System II. Endocannabinoid Role in Emotional Reactivity and Mood Tone III. EVects of Exogenously Administered Cannabinoid Agonists and Antagonists IV. Enhancement of the Endogenous Cannabinoid Tone V. Faah-Knockout Phenotype VI. Conclusions References Observational studies in humans suggest that exposure to marijuana and other cannabis-derived drugs produces a wide range of subjective eVects on mood tone and emotionality. These observations have their counterpart in animal studies, showing that cannabinoid agonists strongly [...]
Lire la suiteAdverse effects of medical cannabinoids : a systematic review T. Wang, J-P. Collet, S. Shapiro, M.A. Ware, Canadian Medical Association Journal, 2008,178,13, 1669-1678 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/pdf/20080617s00017p1669.pdf Abstract Background : The therapeutic use of cannabis and cannabisbased medicines raises safety concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most safety information comes from studies of recreational use. Methods : We performed a systematic review of safety studies of medical cannabinoids published over the past 40 years to create an evidence base for cannabis-related adverse events and to facilitate future cannabis research initiatives. We critically evaluated [...]
Lire la suitehttps://www.ncbi.nlm.nih.gov/books/NBK425767/ The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US); 2017 Jan 12. ISBN-13: 978-0-309-45304-2ISBN-10: 0-309-45304-6 Copyright and Permissions Hardcopy Version at National Academies Press Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for [...]
Lire la suiteBibliographie Cannabinoïdes et Epilepsie Docteur Christian SUEUR, GRECC, septembre 2018. AGUIRRE-VELASQUEZ C.G. : Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with refractory Epilepsy, Hindawi, Neurology Research International, 2017, ID 2985729, 5 p. American Academy of Neurology : Medical marijuana liquid extract may bring hope for children with severe epilepsy, American Academy of Neurology Press, 2015. https://www.aan.com/PressRoom/Home/PressRelease/1364 AMES F.R., CRIDLAND S. : Anticonvulsivant effect of cannabidiol, South Africa Medical Journal, 1986, 69, 1, 14. ANDERSON P. : Positive Topline Results with Cannabidiol (Epidiolex) in Dravet Syndrome, medscape.com/viewarticle/860357_print, 2016 BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Cannabinoids : is there [...]
Lire la suiteDr Christian Sueur GRECC (Groupe de Recherches et D’Etudes Cliniques sur les Cannabinoïdes) Aout 2018 Certains parents, surtout aux USA[1], ont adopté depuis le début des années 2000, le cannabis comme traitement médical pour calmer leurs enfants autistes violents et agités, ou présentant des comportements d’automutilation. Au Canada également, des parents militent pour obtenir l’autorisation de traiter leur enfant autiste avec des cannabinoïdes.[2] Il en est de même en Israël.[3] Il existe très peu de littérature sur le sujet, et à notre connaissance, aucune étude clinique randomisée.[4] Les questions cliniques et thérapeutiques complexes que posent les comportements d’automutilation chez nos patients autistes constitue un véritable défi : le [...]
Lire la suite